In the past few days, Nvidia’s shares have lost billions in market value and the chipmaker has slipped off its perch as the most valuable stock on Wall Street. But the concerns may be short lived.

Nvidia’s stock had been falling since it briefly overtook Microsoft as Wall Street’s most valuable last week, and it was down nearly 13% in just three days, its worst such stretch since 2022. The company's $2.97 trillion market capitalization puts it behind Microsoft, at $3.34 trillion, and Apple, at $3.22 trillion.

Because Nvidia has become so massive in size, the movements for its stock carry extra weight on the S&P 500 and other indexes. It was the heaviest weight by far on the S&P 500 Monday.

Market watchers would rather there be more diversification, having concerns seeing just Nvidia and a handful of other companies responsible for much of the S&P 500’s returns recently. They would prefer a market where many stocks are participating in the gains.

There's been nearly insatiable demand for Nvidia’s chips to power artificial intelligence applications and the company has played a big role in the U.S. stock market's recent record runs even as the economy’s growth slows under the weight of high interest rates. But the AI boom is moving at such a rapid pace that it’s raised worries about a possible bubble in the stock market and too-high expectations among investors.

Still, investor concerns may be calming, as Nvidia Corp.'s stock is up more than 5% in trading on Tuesday. The rebound for Nvidia helped the Nasdaq composite rise and head toward its first gain in four days.

Derren Nathan, head of equity research at Hargreaves Lansdown, said in a statement that while Nvidia's stock has declined in recent days, one must also look at the bigger picture.

“The shares have still gained 190% on a 12-month view, so it’s no surprise some investors are locking in some profits,” he said.

Nathan also isn't concerned about potential wider spread implications. "Although Nvidia has sneezed, the wider market hasn’t caught a cold with a mixture of less extreme movements in both directions for the rest of the Magnificent 7,” he said.

The Magnificent 7, which include Alphabet, Amazon, Apple, Meta Platforms, Microsoft, Nvidia and Tesla, are a small group of stocks that are responsible for a big chunk of the U.S. stock market's total return.

Investors may also be welcoming a better-than-expected consumer confidence reading and a solid job market. America’s employers added a strong 272,000 jobs last month, a sign that companies are still confident enough in the economy to keep hiring despite persistently high interest rates.

Long term, the market may remain upbeat on Nvidia's prospects. Analysts estimate that the company’s revenue for the fiscal year that ends in January 2025 will reach $119.9 billion — about double its revenue for fiscal 2024 and more than four times its receipts the year before that.

Share:
More In Business
Poll: More Americans think companies benefit from legal immigration
A new poll finds U.S. adults are more likely than they were a year ago to think immigrants in the country legally benefit the economy. That comes as President Donald Trump's administration imposes new restrictions targeting legal pathways into the country. The Associated Press-NORC Center for Public Affairs Research survey finds Americans are more likely than they were in March 2024 to say it’s a “major benefit” that people who come to the U.S. legally contribute to the economy and help American companies get the expertise of skilled workers. At the same time, perceptions of illegal immigration haven’t shifted meaningfully. Americans still see fewer benefits from people who come to the U.S. illegally.
Tylenol maker rebounds a day after unfounded claims about its safety
Shares of Tylenol maker Kenvue are bouncing back sharply before the opening bell a day after President Donald Trump promoted unproven and in some cases discredited ties between Tylenol, vaccines and autism. Trump told pregnant women not to use the painkiller around a dozen times during the White House news conference Monday. The drugmaker tumbled 7.5%. Shares have regained most of those losses early Tuesday in premarket trading.
Load More